

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Breztri (budesonide/glycopyrrolate/formoterol)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Breztri (budesonide/glycopyrrolate/formoterol)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Breztri (budesonide/glycopyrrolate/formoterol) may be approved if the following criteria are met:

- I. Individual is using for the treatment of chronic obstructive pulmonary disease (COPD);

AND

- II. Individual is currently utilizing an inhaled corticosteroid (ICS)/long-acting beta-2 agonist (LABA) agent but requires additional treatment for COPD symptoms or exacerbations (GOLD 2020);

OR

- III. Individual is currently utilizing a long-acting muscarinic antagonist (LAMA)/long-acting beta-2 agonist (LABA) agent but requires additional treatment for COPD symptoms or exacerbations (GOLD 2020).

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. Available from: <http://goldcopd.org>.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.